I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023
IMAB Stock | USD 0.98 0.05 5.38% |
About 55% of I Mab's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding I Mab suggests that some traders are interested. The current market sentiment, together with I Mab's historical and current headlines, can help investors time the market. In addition, many technical investors use I Mab stock news signals to limit their universe of possible portfolio assets.
IMAB |
I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023 Published Mar. 20, 2023 at 200 AM HST Updated 17 minutes ago GAITHERSBURG, Md. and SHANGHAI, China , March 20, 2023 PRNewswire -- I-Mab the Compa
Read at hawaiinewsnow.com
I Mab Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards I Mab can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
I Mab Fundamental Analysis
We analyze I Mab's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of I Mab using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of I Mab based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
I Mab is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
I Mab Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with I Mab stock to make a market-neutral strategy. Peer analysis of I Mab could also be used in its relative valuation, which is a method of valuing I Mab by comparing valuation metrics with similar companies.
Peers
I Mab Related Equities
ERAS | Erasca | 12.94 | ||||
LYEL | Lyell Immunopharma | 5.26 | ||||
DSGN | Design Therapeutics | 4.67 | ||||
APLS | Apellis Pharmaceuticals | 4.39 | ||||
IMVT | Immunovant | 2.09 | ||||
KYMR | Kymera Therapeutics | 1.90 | ||||
BPMC | Blueprint Medicines | 1.29 | ||||
FHTX | Foghorn Therapeutics | 0.50 | ||||
AKRO | Akero Therapeutics | 0.28 | ||||
STTK | Shattuck Labs | 0.91 | ||||
KRYS | Krystal Biotech | 1.27 | ||||
GLUE | Monte Rosa | 1.35 | ||||
ASND | Ascendis Pharma | 1.89 | ||||
CGEM | Cullinan Oncology | 2.08 | ||||
NRIX | Nurix Therapeutics | 2.80 | ||||
BGNE | BeiGene | 4.30 | ||||
RVMD | Revolution Medicines | 10.46 |
Complementary Tools for IMAB Stock analysis
When running I Mab's price analysis, check to measure I Mab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy I Mab is operating at the current time. Most of I Mab's value examination focuses on studying past and present price action to predict the probability of I Mab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move I Mab's price. Additionally, you may evaluate how the addition of I Mab to your portfolios can decrease your overall portfolio volatility.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |